TY - JOUR
T1 - Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure
AU - Aleksova, Aneta
AU - Masson, Serge
AU - Maggioni, Aldo P.
AU - Lucci, Donata
AU - Urso, Renato
AU - Staszewsky, Lidia
AU - Ciaffoni, Stefano
AU - Cacciatore, Giuseppe
AU - Misuraca, Gianfranco
AU - Gulizia, Michele
AU - Mos, Lucio
AU - Proietti, Gianni
AU - Minneci, Calogero
AU - Latini, Roberto
AU - Sinagra, Gianfranco
PY - 2012/4
Y1 - 2012/4
N2 - Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF
AB - Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF
KW - Aldosterone
KW - Candesartan
KW - Heart failure
KW - Left ventricular ejection fraction
KW - Natriuretic peptide
UR - http://www.scopus.com/inward/record.url?scp=84862756380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862756380&partnerID=8YFLogxK
U2 - 10.1007/s10557-012-6370-8
DO - 10.1007/s10557-012-6370-8
M3 - Article
AN - SCOPUS:84862756380
VL - 26
SP - 131
EP - 143
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 2
ER -